GSK to Buy Nuvalent for $10.6 Billion in Oncology Push
By Adria Calatayud
GSK said it reached a deal to buy cancer-drug developer Nuvalent for $10.6 billion, as the U.K. pharmaceutical company continues to branch out into oncology.
The acquisition is set to give GSK ownership of three drug candidates for lung cancer, two of which are currently under review by the U.S. Food and Drug Administration for approval this year, GSK said Tuesday. The deal also continues GSK's recent efforts to rebuild its oncology business.
GSK said it would launch a tender offer of $124 a share in cash for Nuvalent, or a 40% premium to the target's Monday closing price of $88.49. GSK said its aggregate investment is estimated to be $9.4 billion given that Nuvalent brings cash with it.
Nuvalent has two experimental drugs for lung cancer in late-stage development, zidesamtinib and neladalkib. GSK said the deal accelerates its entry into lung-cancer treatment and offers new sales growth opportunities.
GSK said the acquisition is expected to contribute to revenue growth from 2027 and strengthen its core operating profit, helping offset the loss of patent protection for HIV drug dolutegravir over 2028-30.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
June 09, 2026 02:40 ET (06:40 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
United States